Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FORADIL vs AEROLATE JR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Formoterol is a long-acting beta2-adrenergic receptor agonist (LABA) that relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.
Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.
Long-term maintenance treatment of asthma,Prevention of exercise-induced bronchospasm,Maintenance treatment of chronic obstructive pulmonary disease (COPD)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
Inhalation: 12 mcg twice daily (every 12 hours) via Foradil Aerolizer.
1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.
Terminal half-life: 7-10 hours. Steady-state achieved within 3-5 days; clinical context: allows twice-daily dosing for bronchodilation.
Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold.
Metabolized primarily by hepatic glucuronidation and to a lesser extent by CYP2D6, CYP2C19, and CYP2C9.
Primarily metabolized in the liver by cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4. Metabolism is saturable at high concentrations.
Renal (60% as unchanged drug and metabolites) and fecal (40% as metabolites).
Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%.
61% bound to plasma proteins, primarily albumin.
Approximately 70% bound to plasma proteins, primarily albumin.
6.0 L/kg (extensive tissue distribution, indicating high penetration into lungs and peripheral tissues).
Volume of distribution: 0.3-0.5 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding, but limited by protein binding.
Inhalation: ~30% (systemic absorption from lungs; oral bioavailability negligible due to first-pass metabolism).
Oral bioavailability: Approximately 50% due to first-pass metabolism. Inhalation bioavailability: Variable, with 10-20% reaching systemic circulation; remainder swallowed and undergoes first-pass metabolism.
No dose adjustment required for renal impairment.
No adjustment required as drug is primarily hepatically metabolized.
No specific dose adjustment recommended; use caution in severe hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Children 5 years and older: 12 mcg inhalation twice daily. No dosing established for children under 5 years.
Children 4-11 years: 1 inhalation (35 mcg) twice daily; children 12-17 years: same as adult.
No specific dose adjustment; monitor for adverse effects due to potential comorbidities.
No specific dose adjustment; initiate at lower end of dosing range due to potential comorbidities.
LABAs increase the risk of asthma-related death; Foradil should only be used in patients with asthma not adequately controlled on asthma controller medications or whose disease severity warrants initiation of both an inhaled corticosteroid and a LABA.
None.
Increased risk of asthma-related death,Deterioration of disease and acute episodes may occur and should be treated with a short-acting beta2-agonist,Cardiovascular effects (increased heart rate, blood pressure, ECG changes),Hypokalemia and hyperglycemia may occur,Paradoxical bronchospasm may occur and require immediate discontinuation,Do not use with other LABAs
Concurrent illness (especially with fever), smoking cessation, drug interactions, and hepatic or cardiac impairment can significantly alter theophylline clearance. Serum levels must be monitored due to narrow therapeutic index. Use with caution in patients with peptic ulcer, seizure disorders, or hyperthyroidism.
Hypersensitivity to formoterol or any ingredient in the formulation,Use as monotherapy in asthma without concomitant inhaled corticosteroid,Treatment of acute asthma symptoms or exacerbations
Hypersensitivity to theophylline or any component of the formulation.
No specific food interactions. Grapefruit/grapefruit juice may increase systemic exposure via CYP3A4 inhibition; avoid concurrent use.
High-fat meals may delay absorption. Charcoal-broiled foods and high-protein diets can increase clearance. Avoid concurrent consumption of large amounts of caffeine.
FDA Pregnancy Category C. In animal studies, formoterol fumarate (active ingredient of FORADIL) showed adverse effects on fetal development at high doses, including increased fetal loss, decreased fetal weight, and skeletal variations. There are no adequate and well-controlled studies in pregnant women. During first trimester, risk cannot be ruled out. Second and third trimesters: potential risk of maternal beta-agonist effects causing uterine relaxation and delayed labor. Use only if potential benefit justifies potential risk to fetus.
FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used near term due to beta-agonist effects; avoid for tocolysis.
Formoterol is excreted in human milk in small amounts. M/P ratio not established. Caution should be exercised when administered to nursing women. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for FORADIL and any potential adverse effects on the breastfed infant from the drug or underlying maternal condition.
Excreted in breast milk; M/P ratio 2.5. Use caution; may cause tremors or tachycardia in infant. Consider risk-benefit.
No specific dose adjustments are recommended for FORADIL during pregnancy based on pharmacokinetic changes. However, use the lowest effective dose to control asthma symptoms. Monitor for potential increased need for rescue medication due to pregnancy-related changes in asthma severity. No data indicate significant pharmacokinetic changes requiring dosing modification.
Pregnancy may reduce plasma concentrations due to increased clearance; consider dose adjustment based on clinical response. Monitor for hypokalemia.
FORADIL (formoterol fumarate) is a long-acting beta2-agonist (LABA) indicated for maintenance treatment of asthma and COPD, but must not be used as monotherapy for asthma without concomitant inhaled corticosteroid. Onset of bronchodilation occurs within 5-10 minutes, peaking at 1-3 hours, with duration up to 12 hours. Not for acute bronchospasm. Risk of paradoxical bronchospasm; discontinue if occurs. Monitor for increased heart rate, blood pressure, and QTc prolongation. Caution in patients with cardiovascular disorders, seizure disorders, thyrotoxicosis, or diabetes.
AEROLATE JR (theophylline) is a bronchodilator used for asthma and COPD. Due to narrow therapeutic index, monitor serum levels (target 5-15 mcg/m L). Caffeine and smoking affect metabolism; smoking cessation may require dose reduction. Avoid in seizure disorders or peptic ulcer.
Use FORADIL exactly as prescribed; do not use to relieve sudden breathing problems.,Always have a fast-acting rescue inhaler (e.g., albuterol) for acute symptoms.,Do not use more than 2 inhalations every 12 hours; maximum daily dose is 48 mcg.,Rinse mouth with water after each use to reduce risk of thrush (if using with ICS).,Seek medical help immediately if breathing worsens, chest tightness, or hives develop.,Inform your doctor if you have heart disease, high blood pressure, seizures, thyroid problems, or diabetes.,Store capsules in blister pack, use only with provided Aerolizer inhaler; do not swallow capsules.
Take exactly as prescribed; do not change dose without consulting doctor.,Avoid excessive caffeine (coffee, tea, soda, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, seizures.,Do not smoke or abruptly stop smoking; notify doctor if smoking habits change.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FORADIL vs AEROLATE JR, answered by our medical review team.
FORADIL is a Bronchodilator that works by Formoterol is a long-acting beta2-adrenergic receptor agonist (LABA) that relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.. AEROLATE JR is a Bronchodilator that works by Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FORADIL and AEROLATE JR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FORADIL is: Inhalation: 12 mcg twice daily (every 12 hours) via Foradil Aerolizer.. The standard adult dose of AEROLATE JR is: 1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FORADIL and AEROLATE JR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FORADIL is classified as Category C. FDA Pregnancy Category C. In animal studies, formoterol fumarate (active ingredient of FORADIL) showed adverse effects on fetal development at high doses, including increased fetal. AEROLATE JR is classified as Category C. FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used nea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.